Chronic Eosinophilic Pneumonia (CEP) is a rare idiopathic eosinophilic lung disease characterized by a triad of pulmonary symptoms, radiographic findings and peripheral and/or lung eosinophilia. CEP is usually treated with oral corticosteroids however, treatment durations commonly exceed 12 months, relapses occur in ½ of patients and adverse effects of steroid use are common. We report a case of an 11-year-old female with corticosteroid refractory CEP who experienced clinical remission after initiation of dupilumab, a monoclonal antibody therapy approved for eosinophilic or steroid dependent asthma that inhibits IL-4 and IL-13. This case demonstrates the potential role of biologic agents in CEP.